Completed PHASE1 INTERVENTIONAL 2-arm NCT06423872

A SAD Study of ZT002 Injection in Healthy Participants

A Phase 1, Randomized, Parallel Assignment, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of ZT002 in Healthy Participants

Sponsor: Beijing Hospital

Conditions Type 2 Diabetes Mellitus

Interventions Placebo ZT002

Updated 3 times since 2024 Last updated: May 16, 2024 Started: Jun 19, 2023 Primary completion: Oct 20, 2023 Completion: Dec 8, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06423872, this PHASE1 trial focuses on Type 2 Diabetes Mellitus and remains completed. Sponsored by Beijing Hospital, it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2024 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Hospital
Beijing QL Biopharmaceutical Co.,Ltd

Data source: Beijing QL Biopharmaceutical Co.,Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China